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Naturally occurring proteolytic fragments of pros-
tatic acid phosphatase (PAP248-286 and PAP85-
120) and semenogelins (SEM1 and SEM2) form amy-
loid fibrils in seminal fluid, which capture HIV virions
and promote infection. For example, PAP248-286 fi-
brils, termed SEVI (semen-derived enhancer of viral
infection), can potentiate HIV infection by several
orders of magnitude. Here, we design three disrup-
tive technologies to rapidly antagonize seminal amy-
loid by repurposing Hsp104, an amyloid-remodeling
nanomachine from yeast. First, Hsp104 and an
enhanced engineered variant, Hsp104A503V, directly
remodel SEVI and PAP85-120 fibrils into non-amyloid
forms. Second, we elucidate catalytically inactive
Hsp104 scaffolds that do not remodel amyloid struc-
ture, but cluster SEVI, PAP85-120, and SEM1(45–
107) fibrils into larger assemblies. Third, we modify
Hsp104 to interact with the chambered protease
ClpP, which enables coupled remodeling and degra-
dation to irreversibly clear SEVI and PAP85-120 fi-
brils. Each strategy diminished the ability of seminal
amyloid to promote HIV infection, and could have
therapeutic utility.
INTRODUCTION
HIV is a global epidemic that has killed nearly 30 million people
since its discovery (UNAIDS, 2010). The HIV pandemic is most
severe in the developing world. In Sub-Saharan Africa, 5% of
adults are infected with the virus (UNAIDS, 2011). Nearly 80%
of HIV infections are acquired through heterosexual transmission
(Gray et al., 2001; Pilcher et al., 2004; Royce et al., 1997), and
endogenous peptides in semen play a critical role in the spread
of this retrovirus (Arnold et al., 2012; Mu¨nch et al., 2007; Roan
et al., 2011).
Naturally occurring fragments of proteins abundant in semen
form amyloid fibrils (Usmani et al., 2014), and the unique compo-
sition of semen drives the fibrillization process (Olsen et al.,
2012). Specifically, proteolytic fragments of prostatic acid phos-1074 Chemistry & Biology 22, 1074–1086, August 20, 2015 ª2015 Elphatase (PAP248-286 [SEVI] and PAP85-120), semenogelin 1
(SEM1), and semenogelin 2 (SEM2) form fibrils that enhance
HIV infectivity by several orders of magnitude under conditions
of limiting viral inoculum, whereas the soluble, non-amyloid pep-
tides have no effect (Arnold et al., 2012; Mu¨nch et al., 2007; Roan
et al., 2011). Polylysine and other cationic polymers such as pol-
ybrene can enhance HIV infection in cell culture, but are not as
effective at low concentrations as SEVI fibrils (Mu¨nch et al.,
2007; Sievers et al., 2011; Yolamanova et al., 2013). Semen-
derived fibrils are highly basic and contain a large proportion of
lysine and arginine residues. These charged fibrils promote HIV
infection by neutralizing the inherent electrostatic repulsion be-
tween the negatively charged surfaces of HIV virions and target
cells, and, through direct binding to virions, fibrils simultaneously
promote viral binding to the cell surface (Roan et al., 2009). Am-
yloid fibrils are implicated in numerous neurodegenerative and
systemic diseases, and they are notoriously difficult to clear
due to their self-templating character and stability, which lies
at the extremes of protein-based structures (Knowles et al.,
2014). Nonetheless, eliminating semen-derived fibrils could
massively reduce viral transmission (Castellano and Shorter,
2012). This approach could be advantageous because it tar-
gets host-encoded viral-enhancing factors rather than the viral
machinery itself. However, because diverse polypeptides form
fibrils in semen that promote viral infection, we explored remod-
eling factors with activity against diverse amyloids, rather than
agents with specialized activity against any single peptide (Cas-
tellano and Shorter, 2012; Sievers et al., 2011).
With this design principle in mind, we turned to Hsp104, an
amyloid-remodeling nanomachine and AAA+ protein (Shorter,
2008). Hsp104 renatures amorphous protein aggregates
following thermal or chemical stress, and catalytically decon-
structs diverse amyloid fibrils (DeSantis et al., 2012; Glover
and Lindquist, 1998; Jackrel et al., 2014; Klaips et al., 2014;
Liu et al., 2011; Lo Bianco et al., 2008; Shorter and Lindquist,
2004, 2006). Hsp104 is a generalist, and is adapted to remodel
diverse prion conformers and disaggregate a large proportion
of the yeast proteome in response to environmental stress
(Vashist et al., 2010). Despite being highly conserved in eubacte-
ria and eukaryotes, Hsp104 homologs are absent in metazoa
(Shorter, 2008). However, Hsp104 has previously been utilized
in metazoan systems to counteract disease-associated protein
aggregates and amyloid fibrils (Cushman-Nick et al., 2013; Kim
et al., 2013; Lo Bianco et al., 2008; Vashist et al., 2010).sevier Ltd All rights reserved
Here, we exploit the broad-spectrum, amyloid-remodeling ac-
tivity of Hsp104 to antagonize semen-derived amyloid fibrils and
reduce HIV transmission. We devise three disruptive technolo-
gies to antagonize seminal amyloid based on Hsp104. Our find-
ings provide insight into developing nanomachines to abolish the
infection-enhancing capabilities of seminal amyloid and comple-
menting microbicidal approaches.
RESULTS
Hsp104 Remodels SEVI Fibrils
First, we tested whether Hsp104 can remodel SEVI fibrils. We
assessed fibril remodeling using the amyloid-binding dye,
Thioflavin-T (ThT), and by transmission electron microscopy
(TEM). Incubation of SEVI fibrils with a substoichiometric con-
centration of Hsp104 (PAP248-286:Hsp104 of 6.67:1) reduced
ThT fluorescence intensity to 37% of the initial value after
2 hr, and a further decrease to 27% was observed after 6 hr
(Figure 1A). The ThT fluorescence intensity plateaued after
6 hr, indicating that amyloid fibrils cannot reform rapidly after
Hsp104-mediated remodeling. Hsp104 remodels SEVI fibrils
more rapidly than the green tea polyphenol, epigallocatechin-
3-gallate, which slowly eradicates SEVI fibrils over the course
of 24–48 hr (Hauber et al., 2009). TEM revealed that the products
of Hsp104 remodeling were structures resembling amorphous
protein aggregates (Figure 1B). After 2 hr, SEVI fibrils were
completely converted into these non-amyloid aggregates by
Hsp104, and no further alteration in morphology was observed
after 24 hr. Dose-response analysis of Hsp104-mediated remod-
eling of SEVI fibrils indicates a half-maximal effective concentra-
tion (EC50) value of 0.72 mM (Figure 1C).
We obtained a similar result when SEVI fibrils were incubated
with Hsp104 plus Hsp70 and Hsp40. Hsp70 and Hsp40 are
usually required for disaggregation of amorphous protein aggre-
gates by Hsp104, whereas amyloid remodeling by Hsp104 does
not always necessitate Hsp70 and Hsp40 (DeSantis et al., 2012;
Glover and Lindquist, 1998; Shorter and Lindquist, 2004, 2006,
2008). However, in some instances Hsp70 and Hsp40 can
enhance Hsp104-mediated disassembly of amyloid (DeSantis
et al., 2012; DeSantis and Shorter, 2012b; Lo Bianco et al.,
2008; Shorter, 2011). Hsp70 and Hsp40 alone had no effect on
SEVI fibrils (Figure 1D). By contrast, the ThT fluorescence inten-
sity of SEVI fibrils incubated with Hsp104, Hsp70, and Hsp40
decreased to 36% of the initial value after 2 hr, and a larger
reduction to 16% was observed after 24 hr (Figure 1D).
Thus, there is a slight enhancement in remodeling in the pres-
ence of Hsp70 and Hsp40, particularly after extended incubation
times.
Next, we explored the effects of inactive Hsp104 variants on
SEVI fibril integrity. Hsp104DWB is an ATPase-deficient Hsp104
variant with E285Q and E687Q substitutions at Walker B sites
that are critical for ATP hydrolysis (Bosl et al., 2005). Hsp104DWB
can bind but not hydrolyze ATP, which renders the protein inac-
tive in amyloid remodeling and disaggregation (DeSantis et al.,
2012). Hsp104DWB is also a ‘‘trap’’ mutant, which binds to sub-
strates without releasing them (Bosl et al., 2005). SEVI fibrils
incubated with Hsp104DWB for 24 hr exhibited no change in
ThT fluorescence (Figure 1A). Hsp104DWB had no effect on fibril
integrity (Figure 1E). Thus, Hsp104 actively remodels SEVI fibrilsChemistry & Biology 22, 1074–through cycles of ATP binding and hydrolysis and not merely
through passive binding events.
Next, we tested the efficacy of ClpB, the Escherichia coli ho-
molog of Hsp104, which can renature and remodel disordered
aggregates but has limited ability to disassemble amyloid fibrils
due to altered inter-subunit collaboration (DeSantis et al., 2012).
ClpB did not reduce ThT fluorescence intensity when incubated
with SEVI fibrils (Figure 1A). TEM confirmed that intact SEVI am-
yloid fibrils persisted after incubation with ClpB (Figure 1E). Thus,
ClpB is unable to remodel SEVI fibrils.
To determine whether Hsp104 dissolved SEVI fibrils, we
passaged reactions through a 10-kDa molecular weight cutoff
filter. The resulting filtrate and retentate were analyzed by
SDS-PAGE. Because the PAP248-286 peptide is 4.5 kDa,
only PAP248-286 monomers and dimers pass through the filter
while any higher-order species are retained. At all time points,
Hsp104-remodeled SEVI products were predominately retained
by the filter (Figure 1F). Thus, dissolution of SEVI fibrils into
PAP248-286 monomers or dimers by Hsp104 is not a major
pathway. Rather, as suggested by TEM (Figure 1B), the products
are likely larger non-fibrillar aggregates. Thus, Hsp104 has
limited ability to dissolve SEVI fibrils, unlike several other amy-
loids (DeSantis et al., 2012). Hsp104 has reduced ability to
dissolve specific Sup35 prion strains, but instead converts
them to a mixture of soluble protein and non-templating
aggregated forms (DeSantis and Shorter, 2012b; Shorter and
Lindquist, 2006). Hsp104 transforms SEVI fibrils into another
aggregated form, which likely lacks cross-b structure as indi-
cated by reduced ThT fluorescence (Figure 1A), but can these
aggregated species template the assembly of SEVI fibrils?
To assess whether Hsp104 eliminated the self-templating ac-
tivity of SEVI fibrils, we tested the ability of Hsp104-remodeled
SEVI products to seed fibrillization of PAP248-286. Assembly
of PAP248-286 into SEVI fibrils is accelerated by addition of a
small amount of preformed SEVI fibril seed, which eliminates
the lag phase for nucleation (Ye et al., 2009). In the presence
of 0.1% SEVI fibril seed, the lag phase for assembly was abol-
ished, and monomeric PAP248-286 polymerized into fibrils,
with ThT fluorescence intensity plateauing around 24 hr (Fig-
ure 1G). At this time, unseeded reactions remained in lag phase
(Figure 1G). Importantly, SEVI fibrils pretreated with Hsp104 for
6 hr no longer seeded fibrillization of PAP248-286 (Figure 1G).
Thus, Hsp104 converts SEVI fibrils into altered non-amyloid con-
formers that lack seeding activity.
A Potentiated Hsp104 Variant Remodels SEVI at
Nanomolar Concentrations
Next, we assessed whether a potentiated Hsp104 variant had
improved ability to remodel SEVI fibrils. A missense mutation in
the coiled-coil middle domain of Hsp104, Hsp104A503V, yields
a potentiated variant with elevated ATPase activity, accelerated
substrate translocation rate, and enhanced disaggregase activ-
ity (Jackrel et al., 2014). Hsp104A503V suppresses TDP-43 and
a-synuclein proteotoxicity by dissolution of protein aggregates
and restoration of proper protein localization (Jackrel et al.,
2014; Jackrel and Shorter, 2014; Sweeny et al., 2015).
When tested against SEVI fibrils, Hsp104A503V reduced ThT
fluorescence by a magnitude similar to that observed with
Hsp104 (Figures 1A and 2A). After 2 hr with Hsp104A503V, ThT1086, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1075
Figure 1. Hsp104 Rapidly Remodels SEVI Fibrils to Non-templating Forms
(A) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated), Hsp104 (3 mM), Hsp104DWB (3 mM), or ClpB (3 mM; DnaK (3 mM), DnaJ (0.6 mM), and GrpE
(0.3 mM)) for 0–24 hr. Fibril integrity was assessed via ThT fluorescence. Values represent means ± SEM (n = 3–4).
(B) TEM of SEVI fibrils incubated with buffer (untreated) or Hsp104 (3 mM) for either 2 or 24 hr. Scale bars are indicated.
(C) Dose-response analysis of SEVI fibrils (20 mM monomer) treated with various concentrations of Hsp104 for 6 hr. Fibril integrity was assessed via ThT fluo-
rescence and the EC50 was calculated. Values represent means ± SEM (n = 3).
(D) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated) or the indicated combinations of Hsp104 (3 mM), Hsp70 (1 mM) and Hsp40 (1 mM). Fibril
integrity was assessed via ThT fluorescence. Values represent means ± SEM (n = 4).
(E) TEM of SEVI fibrils incubated with buffer (untreated), Hsp104DWB, or ClpB (3 mM) for 3 hr. Scale bar is indicated.
(F) SEVI fibrils (20 mM monomer) were incubated with buffer (untreated) or Hsp104 (3 mM) for 0–6 hr. The resulting products were passed over a 10 kDa filter.
Filtrate and retentate fractions were processed for SDS-PAGE and silver stain.
(G) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated) or Hsp104 (3 mM) for 6 hr, and the resulting products were used to seed soluble PAP248-
286 (1mM, 0.1% fibril seed) fibrillization. Buffer conditions lacking fibril seedwere included. Fibril assembly wasmonitored by ThT fluorescence. Values represent
means ± SEM (n = 4).
See also Figures S1 and S2.fluorescence decreased to 49% of the initial value, with a
further decrease to 35% after 24 hr (Figure 2A). Non-fibrillar
aggregates accumulated after Hsp104A503V treatment compara-
ble with those observed with Hsp104 (Figure 2B). Indeed,
Hsp104A503V did not dissolve SEVI fibrils (Figure 2C). These ag-
gregates were stable over several days and were unable to seed
assembly of soluble PAP248-286 (Figure 2D). Thus, Hsp104A503V1076 Chemistry & Biology 22, 1074–1086, August 20, 2015 ª2015 Elconverts SEVI fibrils to non-templating species. Remarkably,
dose-response studies of Hsp104A503V-catalyzed remodeling
of SEVI fibrils established an EC50 of 36 nM (Figure 2E), which
is 20-fold lower than the EC50 determined for Hsp104
(Figure 1C). This nanomolar EC50 for SEVI remodeling by
Hsp104A503V is unprecedented and could have therapeutic
potential.sevier Ltd All rights reserved
Figure 2. Hsp104A503V Rapidly Remodels SEVI Fibrils, whereas Hyperactive ClpB Variants Are Inactive
(A) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated) or Hsp104A503V (3 mM) for 0–24 hr and fibril integrity was assessed by ThT fluorescence.
Values represent means ± SEM (n = 4).
(B) TEM of SEVI fibrils incubated with buffer (untreated) or Hsp104A503V (3 mM) for 3 hr. Scale bar is indicated.
(C) SEVI fibrils (20 mM monomer) were incubated with Hsp104A503V (3 mM) for 0–6 hr, and the resulting products were passed over a 10-kDa filter. Filtrate and
retentate fractions were then processed for SDS-PAGE and silver stain.
(D) SEVI fibrils (20 mM monomer) were incubated with buffer (untreated) or Hsp104A503V (3 mM) for 6 hr, and the resulting products were used to seed soluble
PAP248-286 (1 mM, 0.1% fibril seed) fibrillization. Buffer conditions lacking fibril seed were included. Fibril assembly wasmonitored by ThT fluorescence. Values
represent means ± SEM (n = 3).
(E) Dose-response analysis of Hsp104A503V remodeling of SEVI fibrils (20 mM monomer) after 6 hr of treatment. The EC50 is based on ThT fluorescence. Values
represent means ± SEM (n = 6).
(F) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated) or the indicated ClpB variant (3 mM) in the absence (black bars) or presence (gray bars) of
DnaK (3 mM), DnaJ (0.6 mM), and GrpE (0.3 mM) for 6 hr, and fibril integrity was assessed by ThT fluorescence. Values represent means ± SEM (n = 3–4). See also
Figures S1 and S2.Hyperactive ClpB Variants Are Unable to Eliminate SEVI
Fibrils
Next, we assessed whether ClpB activity might also be
enhanced against SEVI fibrils by specific middle-domain muta-
tions that enhance ClpB activity. Thus, we assessed the activity
of three hyperactive ClpB variants: ClpBR356C, ClpBK476C, and
ClpBY503D (Oguchi et al., 2012). None of the hyperactive ClpB
variants reduced ThT fluorescence of SEVI fibrils in the presence
or absence of the E. coli Hsp70 chaperone system: DnaK, DnaJ,Chemistry & Biology 22, 1074–and GrpE (Figure 2F). In fact, in the absence of DnaK, DnaJ, and
GrpE, ClpB and the hyperactive variants increased ThT fluores-
cence of SEVI fibrils (Figure 2F), which might indicate a ClpB ac-
tivity that exposes further ThT-binding sites on SEVI fibrils. DnaK,
DnaJ, andGrpE had no effect on SEVI fibrils alone and prevented
the increase in ThT fluorescence caused by ClpB or ClpBY503D,
but not ClpBR356C or ClpBK476C (Figure 2F). Thus, ClpB is unable
to eliminate amyloid even when its activity is enhanced by hyper-
activating mutations in the middle domain. This finding likely1086, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1077
reflects profound differences in how Hsp104 and ClpB subunits
process substrates for disaggregation (DeSantis et al., 2012,
2014).
Hsp104 and Hsp104A503V Remodel PAP85-120 Fibrils
The relative contribution of each seminal amyloid to enhance-
ment of HIV infection by human semen is uncertain and thus it
is important to isolate amyloid-remodeling factors that remodel
diverse seminal amyloids (Castellano and Shorter, 2012). We
examined whether Hsp104 and Hsp104A503V remodel additional
amyloid fibrils endogenous to seminal fluid, including those
formed by another PAP fragment, PAP85-120 (Arnold et al.,
2012). Hsp104 remodeled PAP85-120 fibrils, whereas ClpB
and Hsp104DWB were inactive (Figure S1A). After 2 hr, Hsp104
reduced ThT fluorescence to 63% of the initial value, and a
further decrease to 39% was observed after 6 hr, indicating
rapid fibril remodeling (Figure S1A). Hsp104 remodels PAP85-
120 fibrils into non-fibrillar aggregates (Figure S1B). Similar
results were obtained with Hsp104A503V (Figures S1C and
S1D). Under these conditions, the ThT fluorescence intensity
decreased more slowly than with Hsp104, and a reduction to
only 67% was observed after 2 hr (Figure S1C). However,
after 24 hr of incubation with Hsp104A503V, ThT fluorescence
decreased to 28% of the initial value (Figure S1C). TEM anal-
ysis also revealed non-amyloid aggregates after treatment with
Hsp104A503V (Figure S1D). Thus, Hsp104 and Hsp104A503V
rapidly remodel SEVI and PAP85-120 fibrils.
Hsp104 and Hsp104A503V Do Not Remodel
SEM1(45–107) Fibrils
Numerous peptide fragments of SEM1 and SEM2 form amyloid
and enhance HIV infection (Roan et al., 2011). We focused
on the SEM1(45–107) fragment as a representative peptide.
ThT fluorescence was unchanged when SEM1(45–107) fibrils
were treated with Hsp104 or Hsp104A503V for 24 hr (Figures
S2A and S2C). This result was verified by TEM, which showed
abundant, dense clumps of SEM1(45–107) fibrils after Hsp104
or Hsp104A503V treatment (Figures S2B and S2D). Thus,
SEM1(45–107) fibrils are refractory to remodeling by Hsp104
and Hsp104A503V, indicating that some feature of SEM1(45–
107) fibrils antagonizes Hsp104 activity.
Hsp104 Promotes Clustering of Seminal Amyloid into
Larger Aggregates
Even though Hsp104DWB and ClpB failed to eliminate cross-b
structure of seminal amyloid as indicated by ThT fluorescence
(Figures 1A, S1A, and S2A), solutions became turbid, indicating
a clustering of fibrils into higher-order conglomerates. Seques-
tration of seminal amyloid into larger aggregated structures
could be a valuable strategy, as it would shield the network of
positive charge presented by fibrils and reduce stimulation of
HIV infection. Indeed, molecular chaperones stimulate clustering
of toxicmisfolded oligomers into larger species in the absence of
any structural reorganization or disassembly of oligomers (Man-
nini et al., 2012). The larger aggregated species mask reactive
surfaces of oligomers and neutralize oligomer toxicity (Mannini
et al., 2012). Importantly, this mechanism is extremely effective,
as significant effects are observed at highly substoichiometric
chaperone levels (Mannini et al., 2012). Moreover, several chap-1078 Chemistry & Biology 22, 1074–1086, August 20, 2015 ª2015 Elerones do not require ATP or ATPase activity to cluster oligomers
(Mannini et al., 2012). By analogy, we wondered whether
Hsp104-based scaffolds might cluster seminal amyloid into
larger aggregates in an ATP-independent manner and neutralize
their ability to promote HIV infection.
We employed turbidity to assess the formation of larger aggre-
gates. GFP was included as a protein control and did not
affect turbidity of any of the seminal amyloid fibrils (Figures
3A–3C). By contrast, the turbidity of SEVI, PAP85-120, and
SEM1(45–107) fibrils increased rapidly upon incubation with
Hsp104, Hsp104DWB, or ClpB (Figures 3A–3C and S3A–S3C).
Thus, Hsp104 remodels the amyloid structure of SEVI and
PAP85-120 fibrils (Figures 1A and S1A) and simultaneously
transforms these conformers into large amorphous aggregates
(Figures 1B, 3A, 3B, and S1B). By contrast, Hsp104 does not
remodel SEM1(45–107) fibrils but clusters them into large aggre-
gates (Figures S2A and 3C). Hsp104DWB and ClpB fail to remodel
the amyloid structure of SEVI, PAP85-120, and SEM1(45–107)
fibrils (Figures 1A, S1A, and S2A), but cluster them into larger
species (Figures 3A–3C and S3A–S3C). A marginally larger in-
crease in turbidity was observed when seminal amyloid fibrils
were incubated with Hsp104DWB in comparison with Hsp104
(Figures 3A–3C). Thus, the seminal amyloid clustering activity
does not require ATP hydrolysis and resembles clustering of
toxic oligomers into larger aggregates by various chaperones
(Mannini et al., 2012).
To confirm this clustering effect, dynamic light scattering (DLS)
was used to investigate the size distribution profile of seminal
amyloid in the absence and presence of Hsp104, Hsp104DWB,
or GFP. DLS of Hsp104 alone revealed species with a diffusion
coefficient of 2.7 3 107 cm2/s and hydrodynamic radius (Rh)
of 7–10 nm (Figure S4A), indicative of a hexamer and consis-
tent with prior studies (Bosl et al., 2005; Narayanan et al.,
2003; Sweeny et al., 2015). Soluble PAP248-286 peptide had
an Rh of 1–2 nm (Figure S4B), which might indicate dimeric
forms or an extended, unstructured monomer (Brender et al.,
2011). By contrast, untreated SEVI fibrils contained an assort-
ment of species with different Rh values (Figure 3D). The major
species had Rh of 6 nm and 1,000–3,000 nm (Figure 3D).
The DLS profile shifted drastically upon addition of Hsp104 or
Hsp104DWB, revealing a broad size distribution of larger particles
ranging in Rh of 100–10,000 nm (Figures 3E and 3F). In
contrast, when SEVI fibrils were incubated with GFP, the size
distribution profile closely resembled the buffer control (Figures
3D and 3G). Similarly, in the presence of Hsp104 and
Hsp104DWB, the size distribution profile of SEM1(45–107) fibrils
shifted toward larger species (Figures 3H–3J). Indeed, aggre-
gated species were now observed with Rh >5,000 nm (Figures
3I and 3J), which are not observed in the buffer control (Fig-
ure 3H). Contrastingly, the particle sizes of SEM1(45–107) fibrils
treated with GFP were more similar to the buffer control (Figures
3H and 3K). These data suggest that Hsp104 and Hsp104DWB
cluster PAP248-286 and SEM1(45–107) into larger aggregated
species.
Next, we tested whether Hsp104 hexamers or ATP were
required for clustering activity. Thus, we explored three mono-
meric Hsp104 fragments: Hsp1041548, comprising the N-termi-
nal domain (NTD), nucleotide-binding domain 1 (NBD1), and
middle domain of Hsp104; Hsp104773908, comprising thesevier Ltd All rights reserved
Figure 3. Hsp104 Promotes the Clustering of Seminal Amyloid Fibrils into Larger Aggregates
(A–C) SEVI (A), PAP85-120 (B), and SEM1(45–107) (C) fibrils (20 mMmonomer) were incubated with Hsp104, Hsp104DWB, ClpB, or GFP (1.8 mMmonomer), and
absorbance at 395 nm was measured for 3 hr. One representative trial is shown.
(D–G) DLS was used to determine the size distribution by mass of SEVI fibrils (20 mM monomer) treated with buffer (D), Hsp104 (E), Hsp104DWB (F), or GFP (G)
(1.8 mM monomer) for 5 min at 25C.
(H–K) DLSwas used to determine the size distribution bymass of SEM1(45–107) fibrils (20 mMmonomer) treatedwith buffer (H), Hsp104 (I), Hsp104DWB (J), or GFP
(K) (1.8 mM monomer) for 5 min at 25C.
(L) SEVI fibrils (20 mM)were incubated with Hsp1041548, Hsp104773908, or Hsp104871908 (1.8 mMmonomer), and absorbance at 395 nmwasmeasured for 3 hr.
One representative trial is shown. See also Figures S3 and S4.small domain of NBD2 and the C-terminal domain of Hsp104,
which can engage basic substrates such as polylysine; and
Hsp104871908, comprising the C-terminal acidic tail of Hsp104
(Cashikar et al., 2002; Hattendorf, 2001). Remarkably, incubationChemistry & Biology 22, 1074–of SEVI, PAP85-120, and SEM1(45–107) fibrils with Hsp1041548,
but not Hsp104773908 or Hsp104871908, resulted in a substantial
increase in turbidity (Figures 3L, S3D, and S3E). Importantly,
Hsp1041548, Hsp104773908, and Hsp104871908 were unable1086, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1079
to remodel SEVI orPAP85fibrils as indicatedbyThTfluorescence
(data not shown). Thus, neither Hsp104 hexamerization nor ATP
hydrolysis is necessary for clustering activity. Rather, determi-
nants in the first 548 amino acids of Hsp104 are sufficient to pro-
mote clustering, whereas the C-terminal 136 amino acids are
unable to promote clustering. Importantly, the inability of the
acidic C-terminal tail of Hsp104 (pI = 3.28), Hsp104871908, to
promote clustering suggests that simply being negatively
charged is not sufficient to induce clustering. Clustering of sem-
inal amyloid into larger conglomerates likely decreases availabil-
ity of virion-binding sites on fibrils via occlusion.
HAP Plus ClpP Degrades SEVI Fibrils and PAP85-120
Fibrils
A potential problemwith the seminal amyloid-remodeling activity
of Hsp104 (Figures 1, 2, and S1) is that peptides might eventually
reform amyloid and promote HIV infection. Likewise, the clus-
tering of seminal amyloid into larger aggregates by various
Hsp104 scaffolds (Figure 3) might also be reversed and enable
fibrils to promote HIV infection. To irrevocably remove seminal
amyloid, we coupled Hsp104 remodeling activity to proteolysis.
For this we employed HAP, an Hsp104 variant carrying three
missense mutations (G739I:S740G:K741F) in a helix-loop-helix
motif that enables association with ClpP, a chambered pepti-
dase from E. coli akin to the proteasome (Tessarz et al., 2008).
HAP maintains disaggregase activity and substrate recognition,
but threads disaggregated products through its central pore and
into the proteolytic chamber of ClpP for degradation (Tessarz
et al., 2008).
Like Hsp104 (Figure 1A), HAP or HAP plus ClpP effectively
remodeled SEVI fibrils, whereas ClpP alone was ineffective
(Figure 4A). After 24 hr, HAP or HAP plus ClpP reduced ThT fluo-
rescence to 22% (Figure 4A). Importantly, this decrease in ThT
fluorescence occurred when SEVI fibrils were subjected to sub-
stoichiometric concentrations of HAP or HAP plus ClpP. In fact,
the EC50 for SEVI fibril remodeling by HAP was 0.36 mM (Fig-
ure 4B), and a slighter higher EC50 of 1.28 mMwas determined
for HAP plus ClpP (Figure 4C), indicating that ClpP reduces HAP
efficacy (Shorter and Lindquist, 2005).
TEM revealed that HAP or HAP plus ClpP converted SEVI
fibrils to amorphous aggregates, similar to those observed with
Hsp104, whereas ClpP alone was ineffective (Figures 1B and
4D). The extreme stability of the amyloid fold resists disruption
by proteases and protein denaturants (Vashist et al., 2010).
Thus, as expected, ClpP alone was unable to degrade SEVI
fibrils (Figure 4E), although it was able to rapidly degrade soluble
PAP248-286 in the presence or absence of HAP (Figure 4E).
Usually ClpP alone cannot degrade folded proteins without a
cognate AAA+ ATPase partner (Yu and Houry, 2007). Indeed,
only small peptides typically shorter than six residues are able
to enter the ClpP chamber for degradation (Wang et al., 1997).
Thus, soluble PAP248-286 is likely to be unfolded and must
effectively access the proteolytic chamber of ClpP. Importantly,
HAP plus ClpP degraded SEVI fibrils over the course of 24 hr
(Figure 4E). Accordingly, HAP plus ClpP eliminated the ability
of SEVI fibrils to seed fibrillization of soluble PAP248-286, con-
firming a deconstruction of amyloid structure (Figure 4F). To
the best of our knowledge, this is the first example of a proteo-
lytic system that can effectively remodel and degrade amyloid.1080 Chemistry & Biology 22, 1074–1086, August 20, 2015 ª2015 ElHAP plus ClpP also rapidly degraded the soluble SEM1(45–
107) and PAP85-120 peptides, whereas ClpP alone was ineffec-
tive (Figures 4G and 4H). HAP plus ClpP was unable to degrade
SEM1(45–107) fibrils (Figure 4G), which is consistent with the
inability of Hsp104 to remodel SEM1(45–107) fibrils (Figure S2A).
By contrast, HAP plus ClpP degraded PAP85-120 fibrils,
whereas ClpP alone was ineffective (Figure 4H). Thus, HAP
plus ClpP degrades SEVI and PAP85-120 fibrils.
Fibril Remodeling, Clustering, and Degradation Reduce
Stimulation of HIV Infection
Finally, we assessed whether these Hsp104-based treatments
affected the ability of seminal amyloids to promote HIV infec-
tion. We employed TZM-bl cells containing a luciferase re-
porter construct under control of the HIV-1 long terminal
repeat to assess the extent of infectivity. First, we determined
that Hsp104, Hsp104A503V, Hsp104DWB, ClpB, Hsp1041548,
Hsp104773908, HAP, ClpP, and GFP had no effect on HIV infec-
tion of TZM-bl cells in the absence of seminal amyloid (Figure 5A).
Moreover, none of the Hsp104 conditions affected cell viability
(Figure 5B; data not shown). Thus, any effects of Hsp104-based
treatments were due to an effect on the fibrils rather than any
direct effect on HIV or on cell viability.
Hsp104 and variants were unable to remodel or degrade
SEM1(45–107) fibrils (Figure S2A, S2C, and 4G), but Hsp104,
Hsp104DWB, and ClpB clustered them into larger conglomer-
ates, whereas GFP was ineffective (Figures 3C and S3C).
Remarkably, this clustering activity reduced the ability of
SEM1(45–107) fibrils to promote HIV infection, whereas GFP
and ClpP were ineffective (Figure 5C). Hsp104DWB converted
SEM1(45–107) fibrils into the largest structures (Figures 3C
and 3J) and accordingly caused the largest reduction in
HIV infection (Figure 5C). The partitioning of SEM1(45–107)
amyloid into larger aggregates likely decreases the availability
of virion-binding sites and thereby restricts the enhancement
of infection (Figure 6). Thus, seminal amyloid fibrils must be
disseminated to counter electrostatic repulsion and promote
HIV infection (Figure 6). Clustering seminal amyloid into
large conglomerates reduces their ability to enhance HIV
infection.
Hsp104-based treatments that remodeled, clustered, or
degraded SEVI fibrils or PAP85-120 fibrils reduced their
ability to promote HIV infection (Figures 5D–5F and 6). Thus,
Hsp104773908, ClpP, and GFP, which could neither remodel,
cluster, nor degrade SEVI fibrils or PAP85-120 fibrils, had no
effect on their ability to enhance HIV infection (Figures 5D
and 5E). Hsp104871908 also had no effect on the ability of
SEVI fibrils to enhance HIV infection (Figure S5). By contrast,
Hsp104, Hsp104A503V, or HAP remodeled SEVI fibrils (Figures
1A, 2A, and 4A) and PAP85-120 fibrils (Figure S1A), and
reduced their ability to enhance HIV infection (Figures 5D–5F).
Hsp104DWB, ClpB, and Hsp1041548, which clustered SEVI
fibrils or PAP85-120 fibrils, also reduced enhancement of HIV
infection (Figures 5D–5F). Finally, HAP plus ClpP degraded
SEVI and PAP85-120 fibrils (Figures 4E and 4H) and strongly
reduced enhancement of HIV infection (Figures 5D and 5E).
Thus, fibril remodeling, clustering, and degradation can all
reduce the enhancement of HIV infection by seminal amyloid
(Figures 6C and 6D).sevier Ltd All rights reserved
Figure 4. HAP Plus ClpP Degrades SEVI Fibrils and PAP85-120 Fibrils
(A) SEVI fibrils (20 mMmonomer) were incubated with buffer (untreated), HAP (3 mM), ClpP (4.5 mM), or HAP (3 mM) plus ClpP (4.5 mM) for 0–24 hr. Fibril integrity was
assessed via ThT fluorescence. Values represent means ± SEM (n = 3–4).
(B and C) Dose-response analysis for HAP (B) and HAP plus ClpP (C) remodeling of SEVI fibrils (20 mM monomer) after 6 hr. The EC50 is based on ThT fluo-
rescence. Values represent means ± SEM (n = 3–7).
(D) TEM of SEVI fibrils (20 mM monomer) incubated with buffer (untreated), HAP (3 mM), ClpP (4.5 mM), or HAP (3 mM) plus ClpP (4.5 mM) for 24 hr. Scale bar
is indicated.
(E) SEVI fibrils or soluble PAP248-286 (20 mM monomer) were treated with HAP (3 mM), ClpP (4.5 mM), or HAP (3 mM) plus ClpP (4.5 mM) for 0–24 hr at 37C.
Reactions were then processed for SDS-PAGE and silver stain.
(F) SEVI fibrils (20 mMmonomer) were incubated with HAP (3 mM) and ClpP (4.5 mM) for 6 hr, and the resulting products were used to seed soluble PAP248-286
(1 mM, 0.1% fibril seed) fibrillization. Buffer conditions lacking fibril seed were included. Fibril assembly was monitored by ThT fluorescence. Values represent
means ± SEM (n = 4).
(G and H) PAP85-120 fibrils or soluble PAP85-120 (G) or SEM1(45–107 fibrils) or SEM1(45–107) (20 mMmonomer) (H) were treated with HAP (3 mM), ClpP (4.5 mM),
or HAP (3 mM) plus ClpP (4.5 mM) for 0–24 hr at 37C, then processed for SDS-PAGE and silver stain.DISCUSSION
We have repurposed an amyloid-remodeling nanomachine from
yeast, Hsp104, to antagonize seminal amyloid and reduce amy-
loid-mediated enhancement of HIV infection. Hsp104, as well as
Hsp104A503V, a potentiated Hsp104 variant (Jackrel and Shorter,
2015), were highly effective at rapidly remodeling SEVI and
PAP85-120 fibrils into non-fibrillar structures. In contrast to a va-
riety of other amyloids (DeSantis et al., 2012), the major Hsp104-
catalyzed remodeling pathwaywas not the conversion of SEVI or
PAP85-120 fibrils to soluble peptide, but rather the conversion ofChemistry & Biology 22, 1074–fibrils to an alternative aggregated state. This remodeling activity
required ATP hydrolysis, as Hsp104DWB was ineffective. The
E. coli Hsp104 homolog, ClpB, was unable to remodel SEVI or
PAP85-120 fibrils, even when activated by mutations in the mid-
dle domain that enhance activity (Oguchi et al., 2012). The
inability of even hyperactive ClpB variants to remodel amyloid
likely reflects profound differences in howHsp104 andClpB sub-
units process substrates for disaggregation (DeSantis et al.,
2012). In stark contrast, Hsp104A503V remodeled SEVI fibrils
(20 mMmonomer) at extremely low concentrations, with a calcu-
lated EC50 value in the nanomolar range. An EC50 this low relative1086, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1081
Figure 5. Hsp104 Reduces the Ability of Seminal Amyloid to Enhance HIV Infection
(A) Effect of Hsp104 variants and ClpP on viral infectivity (left: BL2 virions; right: 89.6 virions) in the absence of any enhancing seminal amyloid. Values represent
means ± SEM (n = 3–6).
(B) MTT assay reveals that the various conditions do not affect TZM-bl cell viability, unlike the TX-100 control. Values represent means ± SEM (n = 3–5).
(C) SEM1(45–107) fibrils (20 mMmonomer) were pretreated with buffer, Hsp104, Hsp104A503V, Hsp104DWB, ClpB, ClpP, or GFP, and HIV infectivity was assessed
in TZM-bl cells by measuring luciferase activity (in relative light units). Different viral strains were used for samples on either side of the solid line. Values represent
means ± SEM (n = 3–6). A one-way ANOVAwith the post hoc Dunnett’s multiple comparisons test was used to compare the untreated SEM1 control with all other
conditions (***p < 0.001).
(D) PAP85-120 fibrils (20 mM) were pretreated with buffer, Hsp104, Hsp104A503V, Hsp104DWB, ClpB, ClpP, HAP plus ClpP, or GFP, and HIV infectivity was as-
sessed in TZM-bl cells and expressed as normalized infectivity to untreated fibril samples. Different viral strains were used for samples on either side of the solid
line. Values represent means ± SEM (n = 3–4). A one-way ANOVA with the post hoc Dunnett’s multiple comparisons test was used to compare the untreated
PAP85-120 control with all other conditions (***p < 0.001).
(E) SEVI fibrils (20 mM) were pretreated with buffer, Hsp104, Hsp104A503V, Hsp104DWB, ClpB, Hsp1041548, Hsp104773908, HAP, ClpP, HAP plus ClpP, or GFP,
and HIV infectivity was assessed in TZM-bl cells and expressed as normalized infectivity to untreated fibril samples. Different viral strains were used for samples
on either side of the solid line. Values represent means ± SEM (n = 3–7). For all experiments in (A) to (E), the protein concentrations used were: Hsp104 (3 mM),
Hsp104A503V (3 mM), HAP (3 mM), HAP-ClpP (3 mM and 4.5 mM, respectively), Hsp104DWB (3 mM), Hsp1041548 (18 mM monomer), Hsp104773908 (18 mM
monomer), ClpB (3 mM), ClpP (18 mMmonomer), and GFP (18 mMmonomer). A one-way ANOVAwith the post hoc Dunnett’s multiple comparisons test was used
to compare the untreated SEVI control with all other conditions (***p < 0.001; **p < 0.01).
(F) SEVI fibrils were treated as in (E) except that the Hsp104 variant concentration was 0.3 mM. HIV infectivity was assessed in TZM-bl cells and expressed as
normalized infectivity to untreated fibril samples. Values represent means ± SEM (n = 3–7). A one-way ANOVA with the post hoc Dunnett’s multiple comparisons
test was used to compare the untreated SEVI control with all other conditions (***p < 0.001; **p < 0.01).
See also Figure S5.
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Figure 6. Hsp104-Based Treatments that
Remodel, Degrade, or Cluster Seminal Amy-
loid Reduce their Ability to Stimulate HIV
Infection
(A) In the absence of seminal amyloid, HIV infec-
tivity is limited by electrostatic repulsion between
the negatively charged surfaces of the viral and
target cell membranes.
(B) Cationic seminal amyloid fibrils shield this
electrostatic repulsion and facilitate HIV infectivity
by bringing virions in closer proximity to the cell
surface.
(C) Hsp104-based treatments remodel (Hsp104
and Hsp104A503V) and degrade (HAP plus ClpP)
SEVI and PAP85-120 fibrils such that their ability to
boost infection is reduced.
(D) Hsp104-based treatments non-catalytically
promote the assembly of seminal amyloid into
higher-order conglomerates, which results in
fewer available sites within fibrils for virion
binding and also acts as a physical barrier to cell
entry.to the quantity of fibrils has not been observed for Hsp104 with
any amyloid, including its natural amyloid substrate, Sup35
prions, where the EC50 (calculated from assays with lower quan-
tities of fibrils relative to Hsp104) ranges from60 to 600 nM de-
pending on the prion strain (DeSantis and Shorter, 2012b).
Importantly, treatment of SEVI and PAP85-120 fibrils with
Hsp104 or Hsp104A503V greatly reduced their ability to enhance
HIV infection (Figure 6C).
Hsp104 engages substrates primarily via two highly con-
served pore loops in NBD1 (256-KYKG-259) and NBD2 (661-
GYVG-664), which project into the central channel of the
hexamer (DeSantis and Shorter, 2012a). The NTD of Hsp104
also contains conserved acidic residues (D108 and D114) that
bind substrate (our unpublished observations) (Barnett et al.,
2005). We have shown previously that Hsp104 directly engages
a range of cross-b conformers formed by diverse polypeptides
(DeSantis et al., 2012). Interestingly, peptide arrays have re-
vealed that Hsp104 displays some amino acid preferences in
the context of linear peptides (Lum et al., 2008). We suspect
that if preferred amino acids are presented in conformational epi-
topes (rather than linear motifs), Hsp104 is likely to recognize
these specifically. The heightened susceptibility of SEVI and
PAP85-120 fibrils to remodeling by Hsp104 and Hsp104A503V
might reflect the high lysine content of PAP248-286 (15.4%)
and PAP85-120 (8.6%) (Castellano and Shorter, 2012). Indeed,
lysine-rich regions provide an important recognition feature for
Hsp104, and polylysine stimulates ATP hydrolysis by Hsp104
(Cashikar et al., 2002; Lum et al., 2008). However, SEM1(45–
107) contains a similar proportion of lysine residues (9.5%),
and SEM1(45–107) fibrils were not remodeled by Hsp104 or
Hsp104A503V. Thus, some other feature of SEM1(45–107) fibrils
likely prevents remodeling by Hsp104. One possibility is that
SEM1(45–107) contains a high proportion of residues that
disfavor Hsp104 binding, including serine, glycine, and histidineChemistry & Biology 22, 1074–(Lum et al., 2008), which are less abundant in PAP248-286 and
PAP85-120 (Castellano and Shorter, 2012). Thus, Hsp104 may
not gain sufficient traction to remodel SEM1(45–107) fibrils.
Alternatively, SEM1(45–107) fibrils might access an amyloid
strain, which is intractable for other reasons such as binding-
site inaccessibility or enhanced stability. A key goal is to innovate
engineered Hsp104 variants that remodel SEM1(45–107) fibrils.
Remodeling amyloid structure by Hsp104 was not necessary,
however, for specific Hsp104 variants to reduce the ability of
seminal amyloid to enhance HIV infection. Thus, even though
Hsp104 did not remodel SEM1(45–107) fibrils, it reduced their
ability to enhance HIV infection. Indeed, Hsp104 clustered
SEM1(45–107) fibrils into large, higher-order aggregates. This
activity did not require ATP hydrolysis as Hsp104DWB promoted
fibril clustering. Indeed, several Hsp104 variants unable to
remodel amyloid structure, including ClpB, and even the mono-
meric Hsp104 fragment, Hsp1041548 encompassing the NTD,
NBD1, and the middle domain, clustered seminal amyloid fibrils
into larger conglomerates with reduced ability to promote HIV
infection. Importantly this effect was specific, as not any protein
could cluster seminal amyloid. Thus, GFP and the Hsp104 frag-
ments, Hsp104773908 and Hsp104871908, were unable to pro-
mote seminal amyloid clustering and had no effect on the
enhancement of HIV infection. The clustering of seminal amyloid
into larger conglomerates likely decreases the availability of
virion-binding sites on fibrils and thereby reduces the enhance-
ment of infection (Figure 6D). Furthermore, these higher-order
assemblies may act as a physical barrier, obstructing virion ac-
cess to the target cell surface (Figure 6D). These findings indicate
that seminal amyloid fibrils must be disseminated to counter
electrostatic repulsion and promote HIV infection (Figure 6B). If
fibrils become too clustered, their ability to promote HIV infection
declines. Future studies will decipher the specific region within
Hsp104 that is sufficient to cause seminal amyloid clustering,1086, August 20, 2015 ª2015 Elsevier Ltd All rights reserved 1083
which could empower the design of peptide-based inhibitors
that impede seminal amyloid functionality.
The clustering activity we observed is reminiscent of the
ability of various molecular chaperones to stimulate the clus-
tering of toxic oligomers into larger species in the absence of
structural reorganization of the oligomers themselves (Mannini
et al., 2012). The larger aggregated species mask the reactive
surfaces of oligomers and neutralize oligomer toxicity (Mannini
et al., 2012). This activity does not require chaperone ATPase
activity or even ATP, and can be driven by substoichiometric
quantities of chaperone (Mannini et al., 2012). Hsp104 stimulates
prionogenesis of various yeast prion proteins, including Sup35
and Ure2, when acting at substoichiometric concentrations
(Shorter and Lindquist, 2004, 2006, 2008; Sweeny et al., 2015;
Sweeny and Shorter, 2008). However, the clustering of amyloid
fibrils into large conglomerates is not an activity we have
observed previously with other substrates. Nonetheless, this ac-
tivity, which does not require Hsp104 ATPase activity or even a
hexameric structure, could play an important role in vivo in the
partitioning of aggregated proteins into higher-order compart-
ments, such as stress foci, JUNQ (juxta-nuclear quality control
compartment), and IPOD (insoluble protein deposit compart-
ment) (Amen and Kaganovich, 2015).
Therapeutically, effective Hsp104 nanomachines could be
used as microbicide applied in the anogenital tract. A potential
problem with remodeling seminal amyloid or clustering amyloid
into higher-order structures is that remodeled peptides might re-
form amyloid, and clustered fibrils might disperse and be able to
enhance HIV infection once again. To avoid this risk and irrevers-
ibly clear seminal amyloid, we developed a strategy that couples
seminal amyloid remodeling to degradation. Thus, we engi-
neered Hsp104 to interact with ClpP, a chambered protease
from E. coli. The modified Hsp104 variant, termed HAP, passes
remodeled substrates into the ClpP chamber for degradation
(Tessarz et al., 2008). Although ineffective against SEM1(45–
107) fibrils, HAP plus ClpP effectively remodeled and degraded
SEVI fibrils and PAP85-120 fibrils. This ability to contemporane-
ously remodel and degrade exceptionally stable amyloid has not
been previously reconstituted using pure components, and
could also prove useful in the removal of pathologic or dis-
ease-associated amyloid fibrils. Coupled fibril remodeling and
degradation could be especially advantageous in instances
where reactivation of the protein sequestered in fibrils is not
beneficial, as with Ab deposits in Alzheimer’s disease (Cushman
et al., 2010).
SIGNIFICANCE
There is a great need for microbicidal agents that interfere
with HIV infectivity without inducing tissue inflammation.
Our studies suggest that seminal amyloid is likely a tractable
target. We have demonstrated that various strategies based
on Hsp104 interfere with the infectivity-enhancing function
of seminal amyloid. The most irreversible of these entails
coupled remodeling and degradation of seminal amyloid
via the HAP-ClpP system. The ability to irrevocably clear
seminal amyloid and block sexual transmission of HIV could
provide a game-changing solution for the global HIV/AIDS
pandemic. Our approach of targeting host protein con-1084 Chemistry & Biology 22, 1074–1086, August 20, 2015 ª2015 Elformers (seminal amyloid) is fundamentally different from
traditional microbicidal approaches that target the virus.
Consequently, we anticipate that this strategy will synergize
with direct antiviral strategies, such that microbicides con-
taining antiviral agents and antiamyloid agents could display
enhanced efficacy.
EXPERIMENTAL PROCEDURES
Peptides and Fibril Formation
Synthetic peptide Hsp104871908 was from Genscript. Synthetic peptides
PAP248-286, PAP85-120, and SEM1(45–107) were from the Keck Biotech-
nology Resource Laboratory (Yale University). Lyophilized peptides were
reconstituted and assembled into fibrils as described previously (Arnold
et al., 2012; Mu¨nch et al., 2007; Roan et al., 2011). In brief, lyophilized
PAP248-286 was dissolved in PBS to 1 mM, passed through a 0.2-mm
filter, and agitated at 37C and 1400 rpm (Eppendorf Thermomixer) for
72 hr. All subsequent SEVI fibrils were assembled by adding 1% fibril
seed to soluble PAP248-286 solutions and agitating at 37C and
1400 rpm overnight. Lyophilized PAP85-120 was dissolved in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) to remove aggregates and separated into
100-ml aliquots. HFIP was removed by drying in a speed vacuum for
30 min. The resulting film was dissolved in Gibco UltraPure water to
1 mM and passed through a 0.2-mm filter, and solutions were agitated at
37C and 1400 rpm for 24–48 hr. Lyophilized SEM1(45–107) was dissolved
in PBS to 0.5 mM, passed through a 0.2-mm filter, and agitated at 37C and
1400 rpm for 7 days. Peptide concentrations were calculated using extinc-
tion coefficients at 280 nm.
Proteins
Hsp104 and ClpB variants were generated using QuikChange mutagenesis
(Agilent). Untagged Hsp104 variants (wild-type, HAP, DWB, and A503V)
were overexpressed in BL21(DE3)-RIL E. coli cells and purified using Affi-
Gel Blue (Bio-Rad) followed by Resource Q anion-exchange chromatography
as described by DeSantis et al. (2014). His-tagged proteins (ClpP, ClpB, GFP,
Hsp1041548, and Hsp104773908) were purified using Ni Sepharose 6 Fast
Flow (GE Life Sciences) following standard procedures. His-tagged ClpP,
ClpB, and Hsp104 variants were overexpressed in BL21(DE3), M15, and
BL21-RIL E. coli cells, respectively, for purification. The reported concentra-
tions of Hsp104 or ClpB refer to the hexamer and ClpP to the 14-mer unless
otherwise indicated. Hsp70, Hsp40, DnaK, DnaJ, and GrpE were from Enzo
Life Sciences.
Fibril Remodeling
For remodeling experiments, fibrils (20 mM monomer) were incubated with
Hsp104, ClpB, or the indicated variant (3 mM) and diluted into an assay buffer
(25 mM HEPES-KOH, 150 mM KOAc, 10 mM Mg(OAc)2 [pH 7.4]) in the pres-
ence of ATP (5 mM) and an ATP regeneration system (0.1 mMATP, 0.02mg/ml
creatine kinase, 10 mM creatine phosphate). Samples were incubated at 37C
for the duration of the experiments. At various time points, aliquots were
removed and analyzed. For ThT fluorescence measurements, samples were
added to a 96-well plate containing 25 mMThT diluted in assay buffer. Changes
in fluorescence intensity (excitation 440 nm, 5 nm bandwidth; emission
482 nm, 10 nm bandwidth) were measured using a Tecan Safire2 microplate
reader.
TEM
For TEM, reaction aliquots were spotted on Formvar carbon-coated grids (EM
Sciences) and stained with 2% uranyl acetate. Samples were visualized using
a JEOL-1010 electron microscope.
Filter Trap
Reactions were centrifuged in Microcon centrifugal filter devices (Amicon) for
25 min at 14,000 relative centrifugal force. Filtrate and retentate fractions were
analyzed by SDS-PAGE using 10%–20% Tris-Tricine peptide gels (Bio-Rad).
Gels were visualized by silver staining (Invitrogen).sevier Ltd All rights reserved
Turbidity
Fibrils (20 mM monomer) were incubated with the indicated concentrations
of Hsp104 variants, and diluted into assay buffer in the presence of ATP
(5 mM) and an ATP regeneration system (0.1 mM ATP, 0.02 mg/ml crea-
tine kinase, 10 mM creatine phosphate). Turbidity was measured as absor-
bance at 395 nm at room temperature on a Tecan Safire2 microplate
reader.
DLS
SEVI fibrils (20 mMmonomer) were incubated for5minwith the indicated pro-
teins (1.8 mM monomeric concentration) and diluted into assay buffer in the
presence of ATP (5 mM). Samples were immediately transferred into dispos-
able cuvettes (Eppendorf) and light scattering at 658 nm was measured using
a DynaPro NanoStar DLS instrument (Wyatt Technology). DLS measurements
of Rh were made at room temperature. Samples were measured using an
acquisition time of 10 s for ten consecutive measurements. Particle transla-
tional diffusion coefficients were calculated from decay curves of autocorrela-
tion of light-scattering data and converted toRh with the Stokes-Einstein equa-
tion. Histograms of mass versus Rh were calculated using a Regularization
algorithm with Dynamics V7 software.
Fibril Degradation
Fibrils (20 mM monomer) were incubated with HAP (3 mM) and ClpP (4.5 mM),
and diluted into an assay buffer in the presence of ATP and an ATP regenera-
tion system (as above). Samples were incubated at 37C for the duration of the
experiments. At given time points, aliquots were removed and analyzed by
SDS-PAGE on peptide gels followed by silver staining (Invitrogen).
Cell Culture and HIV Infection
TZM-bl cells were maintained in DMEM supplemented with 10% fetal
bovine serum and 1% L-glutamine. Prior to infection, seminal amyloid fi-
brils were incubated with Hsp104 (or variants) in a sterile reaction tube
for 3 hr at 37C. Next, these mixtures were diluted 1:2 in DMEM, followed
by a subsequent 1:2 dilution with HIV-1. Samples were allowed to preincu-
bate with the virus for 10 min at room temperature. The virus/protein
mixtures were added in triplicate to TZM-bl cells (104 cells/well) and incu-
bated for 3 hr at 37C and 5% CO2. Virus/protein mixtures were then
removed and replaced with 200 ml of complete media. Luciferase activity
was assessed 3 days after infection using a Luciferase Assay System
(Promega), and luminescence was measured on an MLX Microtiter Plate
Luminometer (Dynex Technologies). Background luminescence from buffer
control samples was subtracted and values were normalized to untreated
fibril samples. HIV-1 strains used included BL2 (CCR5 using primary
isolate; 65 infectious units; 0.45 ng p24) and 89.6 (dual tropic; 500 infec-
tious units; 0.46 ng p24).
Analysis of Cellular Toxicity
Cell viability of TZM-bl cells treated with Hsp104 or variants was
also measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) reduction assay. TZM-bl cells (104 cells/well) were
treated as described in the HIV infectivity assays, except with DMEM re-
placing virus at each step. Protein/DMEM mixtures were removed after
3 hr and replaced with 200 ml of complete media. Plates were incubated
overnight at 37C. The next day, an MTT stock (50 mg of MTT dissolved
in 10 ml of PBS) was mixed in a 1:1 ratio with DMEM to result in the
MTT reagent. Media were removed from all wells on the 96-well plate
and replaced with 125 ml of fresh media. MTT reagent (25 ml) was added
to each well and incubated at 37C for 3–4 hr. Formazan crystals were
dissolved in 150 ml of 0.1 N HCl in isopropanol with 10% Triton X-100.
MTT reduction was assessed the by detection of absorbance at 570 nm
(630 nm reference wavelength) on an MRX Revelation Microplate Reader
(Dynex Technologies).
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